Non-Small Cell Lung Cancer New Indication: Osimertinib in First-Line NSCLC Ulas D. Bayraktar, MD 2023-11-20
Biliary Tract Cancer New Indication: Trastuzumab plus CISplatin-Gemcitabine in Biliary Tract Cancers Ulas D. Bayraktar, MD 2023-11-20
Prostate Cancer New Reference: Enzalutamide in Recurrent Prostate Cancer Ulas D. Bayraktar, MD 2023-11-20
GastroEsophageal Cancer New Reference: DOCEtaxel, OXALIplatin, Capecitabine in Locally Advanced Gastric Cancer Ulas D. Bayraktar, MD 2023-11-20
GastroEsophageal Cancer New Reference: Pembrolizumab with Chemotherapy in Advanced Gastric Cancer Ulas D. Bayraktar, MD 2023-11-20
Multiple Myeloma New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma Ulas D. Bayraktar, MD 2023-11-20
Multiple Myeloma New Indication: Isatuximab, Carfilzomib, Lenalidomide, Dexamethasone for Untreated High-Risk Multiple Myeloma Ulas D. Bayraktar, MD 2023-09-23
Chronic Lymphocytic Leukemia New Reference: Obinutuzumab, ibrutinib, and venetoclax for Untreated CLL Ulas D. Bayraktar, MD 2023-09-23
